.jpg?width=512)
Ajay Piramal began inside his family's established textile businesses, then redirected the group into pharmaceuticals, financial services and other sectors through decades of acquisitions and asset sales. [1][2][3]
From family textiles to pharmaceuticals
Piramal entered his family's business in the late 1970s, a group whose textile operations traced back to his grandfather. After the deaths of his father and later an older brother, he took on greater responsibility for businesses that were already part of the family enterprise. [2][3]
Facing a difficult textile industry, Piramal shifted toward pharmaceuticals and built scale largely through acquisitions, including Nicholas Laboratories in the late 1980s. The move transformed the family platform into a much larger healthcare business. [1][3]
A defining transaction came in 2010 when Piramal sold the domestic formulations business to Abbott Laboratories for $3.8 billion. He subsequently redeployed capital into pharmaceuticals, financial services and other investments, preserving the inherited business base while materially expanding and reshaping it. [1][2]
The Abbott price was consideration for an operating business, not a direct measure of Piramal's personal net worth. The wealth mechanism is better understood through the family's ownership of the assets sold and the capital later redeployed into new businesses, separating company-level transaction proceeds from the value attributable to his own economic interest. [1][2]
Sources for background
Sources reviewed Sep 15, 2026.
- Ajay Piramal · Forbes · Mar 10, 2026
- Piramal family · Forbes · Nov 14, 2017
- The Next Act · Forbes
Comparable Healthcare billionaires
Similar Healthcare billionaires by estimated net worth.
